Ballentine Partners LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the 4th quarter, Holdings Channel reports. The fund acquired 2,762 shares of the medical device company’s stock, valued at approximately $215,000.
Several other hedge funds also recently made changes to their positions in DXCM. Versant Capital Management Inc acquired a new stake in shares of DexCom during the fourth quarter worth about $25,000. Riverview Trust Co lifted its stake in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in DexCom in the third quarter valued at approximately $57,000. Covestor Ltd boosted its holdings in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its position in shares of DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after acquiring an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.
Insider Buying and Selling at DexCom
In other DexCom news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.30% of the stock is owned by corporate insiders.
DexCom Stock Performance
Analyst Upgrades and Downgrades
Several brokerages have issued reports on DXCM. Raymond James lowered their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Citigroup raised their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein lifted their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Finally, Royal Bank of Canada cut their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $99.29.
View Our Latest Report on DXCM
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles
- Five stocks we like better than DexCom
- What is the NASDAQ Stock Exchange?
- Bloom Energy: Powering the Future With Decentralized Energy
- Find and Profitably Trade Stocks at 52-Week Lows
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Short Selling – The Pros and Cons
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.